49.84
  Price3.94%   +1.89
(After Hours: 49.84 0 +0.00%)
Apr-22-21 04:01AM Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021GlobeNewswire
Apr-21-21 08:50AM Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B StudyBenzinga
08:00AM Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis BBusiness Wire
Apr-21-21 06:52AM What's in the Cards for Eli Lilly (LLY) This Earnings Season?Zacks
Apr-17-21 06:00AM Could Vir Biotechnology Be a Millionaire Maker Stock?Motley Fool
Apr-16-21 07:14AM Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EUZacks
Apr-15-21 09:51AM GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19GlobeNewswire
08:59AM UPDATE 2-EMA starts review of GSK's monoclonal antibody to treat COVID-19 patientsReuters
Apr-08-21 08:30AM Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host CellsGlobeNewswire
Apr-06-21 04:01AM Vir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
Apr-05-21 09:08AM Vir Biotech's VIR-7831 Maintains Activity Against California Variant Of COVID-19 InfectionBenzinga
08:00AM Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California VariantGlobeNewswire
Mar-31-21 01:33AM Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & MoreZacks
Mar-29-21 08:44AM Eli Lilly, Vir and Glaxo say Phase 2 trial combining antibodies reduced viral load by 70% at day 7MarketWatch
08:30AM Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19GlobeNewswire
Mar-26-21 12:42PM GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 DrugBenzinga
08:40AM GlaxoSmithKline and Vir Biotech seek FDA emergency authorization for COVID antibody treatmentMarketWatch
Mar-26-21 08:30AM GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19GlobeNewswire
Mar-25-21 10:55AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRACCESSWIRE
Mar-24-21 01:03AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRPR Newswire
Mar-21-21 10:29AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRNewsfile
Mar-18-21 05:13AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRPR Newswire
Mar-16-21 10:33AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRACCESSWIRE
02:09AM Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & MoreZacks
Mar-16-21 07:35AM AstraZeneca to supply U.S. with extra 500,000 doses of COVID-19 antibody-based cocktailMarketWatch
Mar-14-21 09:21AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRNewsfile
06:35AM Can Vir Biotechnology Distinguish Itself In The Vaccine Market?TipRanks
Mar-12-21 09:33AM Vir Biotech (VIR)/Glaxo COVID-19 Drug Cuts Hospitalization RiskZacks
08:04AM Vir Biotechnology, Inc. (VIR) Surges 32.1%: Is This an Indication of Further Gains?Zacks
Mar-12-21 06:20AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRPR Newswire
Mar-11-21 05:12AM Why Vir Biotechnology Stock Soared TodayMotley Fool
04:18AM Biotech Stock Catapults After GSK-Partnered Covid Drug Succeeds In Key TestInvestor's Business Daily
Mar-11-21 12:01PM Biotech Stock Catapults After GSK-Partnered Covid Drug Succeeds In Key TestInvestor's Business Daily
09:25AM Vir Stock Catapults After Its GSK-Partnered Covid Drug Succeeds In New TestInvestor's Business Daily
Mar-11-21 08:38AM Vir’s Covid-19 Antibody Works Well, Sending Shares FlyingBarrons.com
08:19AM The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From ProthenaBenzinga
Mar-11-21 06:45AM Vir Biotech Soars as Covid Therapy Found Effective at Cutting DeathsInvesting.com
05:13AM Vir/GSK's COVID-19 Antibody Therapy Cuts Hospitalization, Deaths by 85%, Seeks FDA Emergency Use NodBenzinga
Mar-10-21 08:22AM Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19GlobeNewswire
12:05PM New Forecasts: Here's What Analysts Think The Future Holds For Vir Biotechnology, Inc. (NASDAQ:VIR)Simply Wall St.
Mar-07-21 08:55AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRNewsfile
Mar-05-21 09:04AM Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to FluMotley Fool
07:54AM NIH stops clinical trials for two experimental antibody COVID-19 treatmentsMarketWatch
Mar-04-21 02:47AM Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & MoreZacks
12:52PM Why Vir Biotechnology Stock Is Falling TodayMotley Fool
Mar-04-21 10:27AM U.S. COVID death toll above 518,000 as Biden adds voice to outrage at Texas and Mississippi for reopeningMarketWatch
08:35AM Are Options Traders Betting on a Big Move in Vir Biotechnology (VIR) Stock?Zacks
Mar-04-21 08:29AM NIH tells Vir that experimental COVID-19 therapy may not benefit patientsMarketWatch
Mar-03-21 04:35AM Vir Stock Craters On Weak Results For Glaxo-Partnered Covid TreatmentInvestor's Business Daily
02:57AM Vir Shares Plummeted Today. What to Know.Barrons.com
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Cap:    |  Volume (24h):